Delivery Order SPE2DR25D9901-SPE2DR26FMJS1

The Defense Logistics Agency awarded a $394,301.40 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler headquartered in Park Ridge, Illinois, for the supply of Pralidoxime Chloride. This delivery order, issued on January 22, 2026, with an ultimate completion date of January 23, 2026, was awarded without set-aside designation, demonstrating the contractor's competitive capability in unrestricted federal procurement. The award is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy that authorizes the issuance of firm fixed-price delivery orders for pharmaceutical products and medical consumables to support Department of Defense healthcare operations worldwide.

DMS Pharmaceutical Group has established itself as a critical supplier within the federal pharmaceutical supply chain, with substantial prior contracting activity through numerous delivery orders issued by the Defense Logistics Agency's Medical Supply Chain division. The company's comprehensive product portfolio encompasses branded and generic prescription medications, over-the-counter drugs, biologics, vaccines, specialty pharmaceuticals, and medical consumables. The underlying PPV-G GEN V contract, awarded on November 13, 2025, carries a ceiling value of $499,999,999 and extends through December 31, 2036, with a 30-month base period followed by three optional 30-month periods, positioning DMS Pharmaceutical Group as one of multiple regional prime vendor contractors supporting recurring medical supply needs of military healthcare facilities globally.